Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

Lymphoma Clinical Trial

Official title:

Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06218602
• Other study ID #: 2023-0581
• Secondary ID: NCI-2024-00282
• Status: Recruiting
• Phase: Phase 2
• Start date: February 19, 2024
• Est. completion date: September 10, 2026

Study information

• Verified date: February 2024
• Source: M.D. Anderson Cancer Center
• Contact: Neeraj Saini, MD
• Phone: (713) 792-4504
• Email: nsaini[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To find out if adding treatment with fecal microbiota transplantation (FMT) is effective at treating gut-related side effects of antibiotic treatment in participants who are receiving standard therapy with anti-CD19 chimeric antigen receptor T-cell (CAR-T cell) therapy.

Description:

Primary Objectives

1. To assess the toxicity of combination of FMT with anti-CD19 Axicabtagene ciloleucel therapy and compare it with standard of care Arm B with anti-CD19 CAR-T arm

2. To assess the response in participants treated with the combination of FMT and Axicabtagene ciloleucel CAR T-cell therapy at day 30 and compare it with standard of care Arm B with anti-CD19 CAR-T arm.

Secondary Objectives

1. To assess PFS and OS among participants with and without FMT.

2. To assess changes in gut microbiome of lymphoma participants after FMT.

3. To assess dynamic changes in serum and stool metabolites after FMT.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: September 10, 2026
• Est. primary completion date: September 10, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. At least 18 years of age on the day of signing informed consent.

2. Histologically/cytologically confirmed diagnosis of B-cell lymphomas.

3. Is being planned to received FDA approved standard of care anti-CD19 Axicabtagene Ciloleucel.

4. Participants must have received or is receiving high-risk broad-spectrum antibiotics for minimum of two days within 180 days of scheduled Axicabtagene ciloleucel infusion. High-risk broad-spectrum antibiotics include carbapenems (meropenem, imipenem, doripenem), anti-pseudomonal antibiotics (cefepime, piperacillin-tazobactam, ceftazidime) or anaerobic antibiotics including metronidazole, clindamycin, amoxicillin-sulbactam.

5. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Evaluation of ECOG is to be performed within 7 days prior to the date of signing study consent.

6. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.

7. Absolute neutrophil counts should be greater than 1000/ul at the time of administration of fecal enema.

8. Adequate hepatic function defined by a total bilirubin level = 1.5 = x the upper limit of normal (ULN)[except if Gilberts syndrome and then total bilirubin = 3x is allowed], an AST, level = 2.5 x ULN, and an ALT level = 2.5 x ULN. If liver metastases are present, then AST and ALT levels must be = 4 x ULN

9. Adequate renal function defined by an estimated creatinine clearance >30 mL/min according to the Cockcroft-Gault formula or by a creatinine clearance measurement from a 24-hour urine collection.

10. Highly effective contraception for both male and female subjects if the risk of conception exists. Highly effective contraception must be used 30 days prior to first study-drug administration, for the duration of trial treatment, and for at least for 12 months after treatment for females and 4 months after treatment for males. Should a female patient (or male participant's sexual partner) become pregnant or should either the female patient (or male participant's partner) suspect she is pregnant while the participant's study-participation is ongoing, the treating physician should be informed immediately.

Exclusion Criteria:

1. If participant received major surgery within last 4 weeks, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.

2. Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.

3. Has a diagnosis of primary immunodeficiency (excluding IgA deficiency).

4. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the study subject's best interest to participate, in the opinion of the treating investigator.

5. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

6. Pregnant or nursing women

7. For women of childbearing age, a positive urine pregnancy test within 72 hours prior to enrollment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

8. Participants with history of irritable bowel disease and inflammatory bowel disease will be excluded from clinical trial.

9. Participants with difficulties in oral administration or at risk of aspiration (e.g., neurological issues)

Related Conditions & MeSH terms

• Lymphoma

Intervention

Drug:
• Fecal Microbiota Transplantation
Given by PO

Procedure:
• Chemotherapy
Given by Infusion
• CAR-T Therapy
Given by Infusion

Locations

Country	Name	City	State
United States	MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and adverse events (AEs)	Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0	Through study completion; an average of 1 year.

External Links

•   MD Anderson Cancer Center